This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Margaret A. Fischl, MD; Douglas D. Richman, MD; Dennis M. Causey, MD; Michael H. Grieco, MD, JD; Yvonne Bryson, MD; Donna Mildvan, MD; Oscar L. Laskin, MD; Jerome E. Groopman, MD; Paul A. Volberding, MD; Robert T. Schooley, MD; George G. Jackson, MD; David T. Durack, MD, DPhil; John C. Andrews, PhD; Sandra Nusinoff-Lehrman, MD; David W. Barry, MD

JAMA. 1989;262(17):2405-2410.

Abstract
We examined the long-term safety and efficacy of zidovudine therapy in 229 subjects with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex who previously participated in a placebo-controlled study of zidovudine. One hundred two placebo recipients (delayed treatment group) and 127 zidovudine recipients (original treatment group) were followed up while receiving zidovudine therapy for a mean of 21 months. Survival rates for the original treatment group were 84.5% and 57.6% at 12 and 21 months, respectively; for the delayed treatment group, 78.8% and 64.6% at 12 and 18 months, respectively; and 78.8% and 47.5% at 12 and 21 months, respectively, for 77 subjects with AIDS and 93.0% and 71.8%, respectively, for 50 subjects with AIDS-related complex in the original treatment group. Adverse reactions decreased over time and newly observed toxic reactions were unusual. The clinical course of these subjects suggests continued survival benefits with long-term zidovudine therapy.

(JAMA. 1989;262:2405-2410)

Author Affiliations
the AZT Collaborative Working Group

From the University of Miami (Fla) (Dr Fischl); the University of California, San Diego (Dr Richman); Los Angeles County—University of Southern California, Los Angeles (Dr Causey); St Luke's—Roosevelt Hospital Center, New York, NY (Dr Grieco); the University of California, Los Angeles (Dr Bryson); Beth Israel Medical Center, New York (Dr Mildvan); Cornell University Medical College, New York (Dr Laskin); Harvard— New England Deaconess Hospital, Boston, Mass (Dr Groopman); the University of California, San Francisco (Dr Volberding); Harvard-Massachusetts General Hospital, Boston (Dr Schooley); the University of Illinois at Chicago (Dr Jackson); Duke University Medical Center, Durham, NC (Dr Durack); and Burroughs Wellcome Co, Research Triangle Park, NC (Drs Andrews, Nusinoff-Lehrman, and Barry). Dr Laskin is now with Merck Sharp and Dohme Research Laboratories, Rahway, NJ. Dr Jackson is now with the London (England) Hospital Medical College.

Footnotes
Reprint requests to the Department of Medicine, R-60A, University of Miami School of Medicine, PO Box 016960, Miami, FL 33101 (Dr Fischl).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model
Hurwitz et al.
Antimicrob. Agents Chemother. 2008;52:4241-4250.
ABSTRACT | FULL TEXT  

Characterization of the functional and growth properties of long-term cell cultures established from a human somatostatinoma.
Galli et al.
Endocr Relat Cancer 2006;13:79-93.
ABSTRACT | FULL TEXT  

Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production
Lewis et al.
Hum Exp Toxicol 2004;23:173-185.
ABSTRACT  

Immunomodulatory Effect of Zidovudine (ZDV) on Cytotoxic T Lymphocytes Previously Exposed to ZDV
Francke et al.
Antimicrob. Agents Chemother. 2002;46:2865-2871.
ABSTRACT | FULL TEXT  

Multidose Pharmacokinetics of Ritonavir and Zidovudine in Human Immunodeficiency Virus-Infected Patients
Cato et al.
Antimicrob. Agents Chemother. 1998;42:1788-1793.
ABSTRACT | FULL TEXT  

Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection
Moore et al.
Arch Intern Med 1996;156:1073-1077.
ABSTRACT  

Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine
Collier et al.
NEJM 1996;334:1011-1018.
ABSTRACT | FULL TEXT  

The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV Infection: Prolonged Evaluation of Protocol 019 of the AIDS Clinical Trials Group
Volberding et al.
JAMA 1994;272:437-442.
ABSTRACT  

HIV Testing, Counseling, and Prophylaxis After Sexual Assault
Gostin et al.
JAMA 1994;271:1436-1444.
ABSTRACT  

Comparison of Long-term Prognosis of Patients With AIDS Treated and Not Treated With Zidovudine
Lundgren et al.
JAMA 1994;271:1088-1092.
ABSTRACT  

Therapy for Human Immunodeficiency Virus Infection
Hirsch and D'Aquila
NEJM 1993;328:1686-1695.
FULL TEXT  

Who Should Be Screened for HIV Infection? A Cost-effectiveness Analysis
McCarthy et al.
Arch Intern Med 1993;153:1107-1116.
ABSTRACT  

Toxic Effects of Zidovudine in Asymptomatic Human Immunodeficiency Virus-Infected Individuals With CD4+ Cell Counts of 0.50x109/L or Less: Detailed and Updated Results From Protocol 019 of the AIDS Clinical Trials Group
Koch et al.
Arch Intern Med 1992;152:2286-2292.
ABSTRACT  

Zidovudine: Five Years Later
McLeod and Hammer
ANN INTERN MED 1992;117:487-501.
ABSTRACT  

The Impact of Human T-Lymphotrophic Virus Type I/II Infection on the Prognosis of Sexually Acquired Cases of Acquired Immunodeficiency Syndrome
Gotuzzo et al.
Arch Intern Med 1992;152:1429-1432.
ABSTRACT  

Survival of Zidovudine-Treated Patients With AIDS Compared With That of Contemporary Untreated Patients
Vella et al.
JAMA 1992;267:1232-1236.
ABSTRACT  

Combination Therapy for HIV Infection: Getting Closer
Fauci
ANN INTERN MED 1992;116:85-86.
ABSTRACT  

Racial and Ethnic Differences in Outcome in Zidovudine-Treated Patients With Advanced HIV Disease
Easterbrook et al.
JAMA 1991;266:2713-2718.
ABSTRACT  

Long-term Safety and Efficacy of Zidovudine in Patients With Advanced Human Immunodeficiency Virus Disease
Moore et al.
Arch Intern Med 1991;151:981-986.
ABSTRACT  

Cost Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients with Human Immunodeficiency Virus (HIV) Infection
Schulman et al.
ANN INTERN MED 1991;114:798-802.
ABSTRACT  

Treatment of Mildly Symptomatic Human Immunodeficiency Virus (HIV) Infection
Hamilton et al.
ANN INTERN MED 1990;113:635-636.
ABSTRACT  

Syngeneic Bone Marrow Transplantation and Adoptive Transfer of Peripheral Blood Lymphocytes Combined with Zidovudine in Human Immunodeficiency Virus (HIV) Infection
Lane et al.
ANN INTERN MED 1990;113:512-519.
ABSTRACT  

Allergy and Immunology
Bukantz and Lockey
JAMA 1990;263:2623-2625.
ABSTRACT  

The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) Infection: A Double-Blind, Placebo-Controlled Trial
Fischl et al.
ANN INTERN MED 1990;112:727-737.
ABSTRACT  

Prolonged Zidovudine Therapy: Confounded by Pneumocystis carinii Prophylaxis?
Odell and Green
JAMA 1990;263:1635-1635.
ABSTRACT  

Prolonged Zidovudine Therapy: Confounded by Pneumocystis carinii Prophylaxis?-Reply
Fischl et al.
JAMA 1990;263:1635-1636.
ABSTRACT  

Living With AIDS
Chaisson
JAMA 1990;263:434-436.
ABSTRACT  

LONG-TERM AZT APPEARS SAFE AND EFFECTIVE
JWatch General 1989;1989:2-2.
FULL TEXT